Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

Tommaso Stroffolini, Piero Luigi Almasio, Marcello Persico, Simona Bollani, Luisa Benvegnù, Giovangiuseppe Di Costanzo, Giuseppe Pastore, Alessio Aghemo, Gianfranca Stornaiuolo, Alessandra Mangia, Pietro Andreone, Maria Stanzione, Giuseppe Mazzella, Giorgio Saracco, Paolo Del Poggio, Savino Bruno

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis. RESULTS: Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7%) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0% vs 58.7%, P = 0.03), had lower transaminase levels (3.3 ± 2.0 vs 3.8 ± 2.5 u.l.n., P = 0.004), and had higher rate of alcohol intake (38.3% vs 22.5%, P <0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95% CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95% CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95). CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.

Original languageEnglish
Pages (from-to)1966-1972
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume103
Issue number8
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Serum
Hepatitis B Surface Antigens
Interferons
Incidence
Transaminases
Interferon-alpha
Regression Analysis
Alcohols
Databases
Liver
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. / Stroffolini, Tommaso; Almasio, Piero Luigi; Persico, Marcello; Bollani, Simona; Benvegnù, Luisa; Di Costanzo, Giovangiuseppe; Pastore, Giuseppe; Aghemo, Alessio; Stornaiuolo, Gianfranca; Mangia, Alessandra; Andreone, Pietro; Stanzione, Maria; Mazzella, Giuseppe; Saracco, Giorgio; Del Poggio, Paolo; Bruno, Savino.

In: American Journal of Gastroenterology, Vol. 103, No. 8, 08.2008, p. 1966-1972.

Research output: Contribution to journalArticle

Stroffolini, T, Almasio, PL, Persico, M, Bollani, S, Benvegnù, L, Di Costanzo, G, Pastore, G, Aghemo, A, Stornaiuolo, G, Mangia, A, Andreone, P, Stanzione, M, Mazzella, G, Saracco, G, Del Poggio, P & Bruno, S 2008, 'Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis', American Journal of Gastroenterology, vol. 103, no. 8, pp. 1966-1972. https://doi.org/10.1111/j.1572-0241.2008.01912.x
Stroffolini, Tommaso ; Almasio, Piero Luigi ; Persico, Marcello ; Bollani, Simona ; Benvegnù, Luisa ; Di Costanzo, Giovangiuseppe ; Pastore, Giuseppe ; Aghemo, Alessio ; Stornaiuolo, Gianfranca ; Mangia, Alessandra ; Andreone, Pietro ; Stanzione, Maria ; Mazzella, Giuseppe ; Saracco, Giorgio ; Del Poggio, Paolo ; Bruno, Savino. / Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. In: American Journal of Gastroenterology. 2008 ; Vol. 103, No. 8. pp. 1966-1972.
@article{01495befbaf84d95a9f210def0ecd7bd,
title = "Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis",
abstract = "BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis. RESULTS: Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7{\%}) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0{\%} vs 58.7{\%}, P = 0.03), had lower transaminase levels (3.3 ± 2.0 vs 3.8 ± 2.5 u.l.n., P = 0.004), and had higher rate of alcohol intake (38.3{\%} vs 22.5{\%}, P <0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95{\%} CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95{\%} CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95{\%} CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95{\%} CI 0.76-1.95). CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.",
author = "Tommaso Stroffolini and Almasio, {Piero Luigi} and Marcello Persico and Simona Bollani and Luisa Benvegn{\`u} and {Di Costanzo}, Giovangiuseppe and Giuseppe Pastore and Alessio Aghemo and Gianfranca Stornaiuolo and Alessandra Mangia and Pietro Andreone and Maria Stanzione and Giuseppe Mazzella and Giorgio Saracco and {Del Poggio}, Paolo and Savino Bruno",
year = "2008",
month = "8",
doi = "10.1111/j.1572-0241.2008.01912.x",
language = "English",
volume = "103",
pages = "1966--1972",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

AU - Stroffolini, Tommaso

AU - Almasio, Piero Luigi

AU - Persico, Marcello

AU - Bollani, Simona

AU - Benvegnù, Luisa

AU - Di Costanzo, Giovangiuseppe

AU - Pastore, Giuseppe

AU - Aghemo, Alessio

AU - Stornaiuolo, Gianfranca

AU - Mangia, Alessandra

AU - Andreone, Pietro

AU - Stanzione, Maria

AU - Mazzella, Giuseppe

AU - Saracco, Giorgio

AU - Del Poggio, Paolo

AU - Bruno, Savino

PY - 2008/8

Y1 - 2008/8

N2 - BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis. RESULTS: Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7%) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0% vs 58.7%, P = 0.03), had lower transaminase levels (3.3 ± 2.0 vs 3.8 ± 2.5 u.l.n., P = 0.004), and had higher rate of alcohol intake (38.3% vs 22.5%, P <0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95% CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95% CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95). CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.

AB - BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis. RESULTS: Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7%) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0% vs 58.7%, P = 0.03), had lower transaminase levels (3.3 ± 2.0 vs 3.8 ± 2.5 u.l.n., P = 0.004), and had higher rate of alcohol intake (38.3% vs 22.5%, P <0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95% CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95% CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95). CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.

UR - http://www.scopus.com/inward/record.url?scp=49349112892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49349112892&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2008.01912.x

DO - 10.1111/j.1572-0241.2008.01912.x

M3 - Article

C2 - 18637087

AN - SCOPUS:49349112892

VL - 103

SP - 1966

EP - 1972

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -